ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo Cytisinicline demonstrated 6x increase in odds of continuous smoking abstinence at 6 months Cytisinicline treatment well tolerated with low rates of adverse events reported Management to host conference call today, May…
/Read More
Refinanced Loan Extends Maturity to December 2024 SEATTLE, Wash. and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced the Company has refinanced its previous debt agreement with…
/Read More
Company to host conference call at 4:30 PM EDT today, May 9, 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, May 9, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced first quarter 2023…
/Read More
SEATTLE, WA and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2023 financial results and provide an update on the…
/Read More
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of Cytisinicline for Treatment of Nicotine Dependence Management to host conference call today, April 20, 2023 at 8:30AM EDT SEATTLE and VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq:…
/Read More